Glaukos Corporation
GKOS
NYSE·Healthcare·Medical - Devices·Mkt cap $10.4B
$179.53
▲ +1.60%
P/E
-55.24
Mkt Cap
$10.4B
52-Wk Range
$73.16–$191.62
52-Week Range
$73.16 - $191.62
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 88.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary micro-scale device platform enabling minimally invasive treatment with reduced surgical trauma
- First-mover advantage in MIGS market with established clinical evidence and broad physician adoption
- Integrated approach combining device technology with pharmaceutical delivery capabilities through iDose TR platform
- Strong intellectual property portfolio protecting core technologies and product innovations
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Moderate growth ahead
Expanding MIGS market adoption as preferred alternative to traditional glaucoma surgeries with lower complication rates
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Hot
+59.5% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying GKOS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of -$0.14 vs -$0.21 consensus (+33.5% surprise). Revenue of $185.6M vs $150.9M expected (+23.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+33.5%
Revenue trend · last 8Q
—
+28%
+25%
+30%
+38%
+36%
+41%
+50%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$96.7M
$105.5M
$106.7M
$124.1M
$133.5M
$143.1M
$150.6M
$185.6M
Margins · last 8Q
Gross
81.7%
Operating
-9.3%
Profit
-9.9%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 20, 2026
vs Industry
How GKOS stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related